Tethis’ Reconfirmed Scientific Advisory Board appoints Prof. Nicola Aceto, Ph.D as Chairman
Tethis S.p.A announced today that in the first meeting of the reconfirmed Scientific Advisory Board held today, Nicola Aceto PhD, Professor of Molecular Oncology at the Swiss Federal Institute of Technology (ETH) Zurich, has been appointed as its new chairman. Prof. Aceto is a world-renowned leader in circulating tumor cell research, and his work on CTC clusters has been published in the highest ranked scientific journals such as Nature and Cell. Tethis is honored to have prof. Aceto leading the precious work of the SAB and looks forward to continue receiving his highly valuable inputs and contributions.
“I’ve been working with Tethis for almost two years now, as a SAB member and as a user of its technology,” said Prof. Aceto. “I believe its liquid biopsy platform is truly compelling and innovative and perfectly suited for CTC and CTC clusters identification and characterization also in the earliest stages of cancer. I am delighted to accept this role and look forward to continue the stimulating interactions with the rest of the highly competent advisory board members”
The other noticeably qualified members of the SAB that will continue to advise Tethis in its R&D and clinical efforts to develop its innovative liquid biopsy platform are: Paolo Milani PhD, one of the company’s founders and Full Professor at the Department of Physics and Director of the Interdisciplinary Centre for Nanostructured Materials and Interfaces at the University of Milan; Claudio Doglioni MD, Head of Pathology Unit at San Raffaele Hospital in Milan and Professor of Pathology at San Raffaele University; Luca Mazzarella MD, PhD Group Leader and Clinical Scientist at European Institute of Oncology (IEO) in Milan and Alfredo Covelli former Vice President and Head, Medical Affairs, Region Europe, Oncology Business at Novartis.
For media enquiries please contact us at email@example.com